KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Operating Expenses: 2014-2025

Historic Operating Expenses for Aurinia Pharmaceuticals (AUPH) over the last 7 years, with Sep 2025 value amounting to $43.7 million.

  • Aurinia Pharmaceuticals' Operating Expenses fell 21.96% to $43.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $195.8 million, marking a year-over-year decrease of 22.62%. This contributed to the annual value of $239.8 million for FY2024, which is 10.25% down from last year.
  • According to the latest figures from Q3 2025, Aurinia Pharmaceuticals' Operating Expenses is $43.7 million, which was down 12.42% from $49.9 million recorded in Q2 2025.
  • In the past 5 years, Aurinia Pharmaceuticals' Operating Expenses ranged from a high of $74.8 million in Q4 2023 and a low of $40.6 million during Q1 2025.
  • Over the past 3 years, Aurinia Pharmaceuticals' median Operating Expenses value was $58.7 million (recorded in 2024), while the average stood at $58.3 million.
  • As far as peak fluctuations go, Aurinia Pharmaceuticals' Operating Expenses skyrocketed by 53.55% in 2021, and later crashed by 36.09% in 2025.
  • Aurinia Pharmaceuticals' Operating Expenses (Quarterly) stood at $56.1 million in 2021, then rose by 0.76% to $56.5 million in 2022, then surged by 32.25% to $74.8 million in 2023, then fell by 17.70% to $61.5 million in 2024, then decreased by 21.96% to $43.7 million in 2025.
  • Its Operating Expenses stands at $43.7 million for Q3 2025, versus $49.9 million for Q2 2025 and $40.6 million for Q1 2025.